Director/PDMR Shareholding
Updated : 14:00
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
10 August 2018
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 8 August 2018, Mr Jurgens Myburgh, Chief Financial Officer of Mediclinic International plc, acquired 20,000 shares in the Company at ZAR 86.82 per share. Accordingly, Mr Myburgh now owns a total of 80,000 shares in Mediclinic International plc.
The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
1. | Details of PDMR / persons closely associated with them ("PCA")
| |||||
a) | Name | Mr Petrus Jurgens Myburgh
| ||||
2. | Reason for the notification
| |||||
a) | Position / status | Chief Financial Officer of the Company
| ||||
b) | Initial notification / amendment | Initial Notification
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a) | Name | Mediclinic International plc
| ||||
b) | LEI | 2138002S5BSBIZTD5I60
| ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a) | Description of the financial instrument
Identification Code | Ordinary Shares
GB00B8HX8Z88
| ||||
b) | Nature of the transaction | Purchase of shares
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information
Aggregated volume
Price |
20 000
ZAR 86.82
| ||||
e) | Date of the transaction | 8 August 2018; 14:21 UTC
| ||||
f) | Place of the transaction | Johannesburg Stock Exchange
|
About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.
Mediclinic comprises 74 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.